Sir, We report failure of linezolid treatment for post-neurosurgical enterococcal meningitis. Our patient was a 72-year-old female who presented to our Neurosurgical Intensive Care Unit with a left-sided thalamic haemorrhage and hydrocephalus for which she required bilateral external ventricular drains (EVDs) on the day of admission. These were Bactiseal TM EVDs that are impregnated with rifampicin and clindamycin to reduce the risk of bacterial colonization. The left-sided EVD was revised 4 days later and both devices were removed 13 days after admission. The day following removal of the EVDs she developed an acute febrile illness and a lumbar puncture was performed. CSF analysis revealed a white cell count of 366/mL (84% polymorphonuclear cells), and cultures grew Enterococcus faecium resistant to ampicillin and susceptible to vancomycin (MIC 0.75 mg/L) and linezolid (MIC 2 mg/L) and with no evidence of high-level gentamicin resistance (MIC 64 mg/L). 1 MICs were determined by Etest. In vitro synergy testing of vancomycin and gentamicin was not undertaken based on the literature that an absence of high-level gentamicin resistance would predict synergy. 1 A repeat lumbar puncture the following day grew an indistinguishable organism. Due to concerns regarding the penetration of intravenous vancomycin into the CSF and a wish to avoid further surgery to gain intrathecal (it) access, treatment was commenced with intravenous linezolid at a dose of 600 mg every 12 h. After 6 and 9 days of linezolid treatment, repeat CSF cultures grew E. faecium. The patient therefore had a new EVD inserted and was treated with 10 days of intravenous (iv) and intrathecal vancomycin (1 g every 12 h iv and 5 mg oncedaily it) and gentamicin (60 mg every 8 h iv and 4 mg oncedaily it) with regular monitoring of blood and CSF antibiotic levels. This management led to clinical and microbiological cure and the EVD was removed. Both the pre-treatment isolate and the isolate grown on day 9 of linezolid therapy were confirmed as E. faecium group D by species-specific PCR at the Health Protection Agency Reference Laboratory, Colindale, London, UK. They had indistinguishable antibiograms and both had a linezolid MIC of 2 mg/L (breakpoint 4 mg/L).
Nosocomially acquired intracranial infections may be caused by a wide array of microorganisms, including staphylococci, enterococci, Gram-negative bacilli and yeasts. In the presence of prosthetic devices, the treatment of choice for infections caused by Gram-positive organisms is removal of the device and iv administration of vancomycin. However, experimental and clinical data suggest that the penetration of vancomycin into CSF is poor and sometimes unpredictable in cases without severe meningeal inflammation. Some authors have reported that in patients with meningitis, continuous intravenous administration of vancomycin may lead to higher penetration, though in patients without meningitis CSF concentrations usually remain below 4 mg/L. 2 The breakpoint concentration for susceptible organisms may not be achieved consistently in patients without severe meningeal inflammation, even when high daily doses of up to 4 g are used. Therefore, some authors advocate intrathecal administration of vancomycin, although a comprehensive evaluation of the benefits has yet to be made and the associated risks, such as ototoxicity, remain unclear. 2 Treatment of ampicillin-resistant enterococcal infections is further complicated by the fact that the activity of vancomycin is bacteriostatic. The CSF may not be sterilized unless bactericidal activity is established by the addition of gentamicin. 1 These factors, and the desire to avoid further surgery to establish intrathecal access, made linezolid an attractive treatment option for our patient. Linezolid is the first licensed member of the oxazolidinone class of antibiotics with activity against almost all Gram-positive pathogens. Excellent tissue penetration and 100% oral bioavailability are notable properties of linezolid and it is approved in Europe and the USA for the treatment of nosocomial pneumonia, skin and soft tissue infections and, in the USA, vancomycin-resistant E. faecium and methicillin-resistant Staphylococcus aureus (MRSA) infections. 3 Linezolid has also been shown to have good penetration into the CNS. 4 A 2007 review of the evidence regarding the use of linezolid for the treatment of patients with CNS infections identified 42 relevant cases. In the 39 patients in whom the responsible pathogen was isolated, those predominantly responsible for the CNS infections were: penicillin-non-susceptible Streptococcus pneumoniae (7; 17.9%), vancomycin-resistant enterococci (6; 15.4%), Nocardia spp. (5; 12.8%), methicillin-resistant Staphylococcus epidermidis (4; 10.3%) and MRSA (3; 7.7%). Of the 42 patients treated with linezolid, 38 were either cured or showed clinical improvement. 5 Case reports of other authors have found that enterococci disappeared from the CSF after as little as 2 days of iv linezolid treatment. 6 This case shows that linezolid may not reliably treat postneurosurgical intracranial infections caused by enterococci even in the absence of prosthetic material. 
